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Background Microvascular obstruction (MVO) following primary percutaneous coronary intervention (PPCI) treatment of ST-seg-
ment elevation myocardial infarction (STEMI) contributes to infarct expansion, left ventricular (LV) remodelling, and
worse clinical outcomes. The REFLO-STEMI trial tested whether intra-coronary (IC) high-dose adenosine or sodium
nitroprusside (SNP) reduce infarct size and/or MVO determined by cardiac magnetic resonance (CMR).
Methods
and results
REFLO-STEMI, a prospective, open-label, multi-centre trial with blinded endpoints, randomized (1:1:1) 247 STEMI pa-
tients with single vessel disease presenting within 6 h of symptom onset to IC adenosine (2–3 mg total) or SNP (500 mg
total) immediately following thrombectomy and again following stenting, or to standard PPCI. The primary endpoint
was infarct size % LV mass (%LVM) on CMR undertaken 24–96 h after PPCI (n ¼ 197). Clinical follow-up was to 6
months. There was no significant difference in infarct size (%LVM, median, interquartile range, IQR) between adenosine
(10.1, 4.7–16.2), SNP (10.0, 4.2–15.8), and control (8.3, 1.9–14.0), P ¼ 0.062 and P ¼ 0.160, respectively, vs. control.
MVO (% LVM, median, IQR) was similar across groups (1.0, 0.0–3.7, P ¼ 0.205 and 0.6, 0.0–2.4, P ¼ 0.244 for adeno-
sine and SNP, respectively, vs. control 0.3, 0.0–2.8). On per-protocol analysis, infarct size (%LV mass, 12.0 vs. 8.3,
P ¼ 0.031), major adverse cardiac events (hazard ratio, HR, 5.39 [1.18–24.60], P ¼ 0.04) at 30 days and 6 months
(HR 6.53 [1.46–29.2], P ¼ 0.01) were increased and ejection fraction reduced (42.5+ 7.2% vs. 45.7+ 8.0%,
P ¼ 0.027) in adenosine-treated patients compared with control.
Conclusions High-dose IC adenosine and SNP during PPCI did not reduce infarct size or MVO measured by CMR. Furthermore,
adenosine may adversely affect mid-term clinical outcome.
Clinical Trial
registration
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Introduction
Primary percutaneous coronary intervention (PPCI) is the default
reperfusion therapy for ST-segment elevation myocardial infarction
(STEMI).1 However, residual mortality (up to 12% at 6 months1) and
morbidity may be partially attributable to sub-optimal microvascular
perfusion.2,3 Microvascular obstruction (MVO) can occur in up to
70% patients when detected with cardiovascular magnetic reson-
ance (CMR) imaging.4,5 Microvascular obstruction may contribute
to infarct expansion, adverse left ventricular (LV) remodelling and
adverse clinical outcomes, independent of infarct size.4,5
Various strategies have been proposed to attenuate MVO6 and
have included calcium channel blockers, nicorandil, atrial natriuretic
peptide, glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, thrombolytics,
and, perhaps most studied, vaso-active agents such as sodium
nitroprusside (SNP)2,7,8 and adenosine.8 – 12 Adenosine inhibits
neutrophil-related processes central to the evolution of MVO and
in a canine model, reduced ischaemia-reperfusion injury (IRI), lim-
ited infarct size, and improved ventricular function.13 Sodium nitro-
prusside is a direct nitric oxide donor that mediates potent
arteriolar vasodilation, inhibits platelet adhesion and promotes anti-
inflammatory processes,14 which effectively reduce MVO in animal
IRI models.15 Previous clinical trials with these agents varied in their
design and they mostly lacked a sensitive method to detect MVO,
which may have contributed to the multiple conflicting results
seen.7–9,12,16,17 Uncertainty remains regarding the potential thera-
peutic impact of these agents.1
We hypothesized that, in patients undergoing PPCI for STEMI,
appropriate doses of intra-coronary (IC) adenosine or SNP deliv-
ered distally to the coronary bed, and again after stent deployment,
was the optimal administration that would reduce infarct size and
MVO as determined by the sensitive measure of in-patient CMR.
Methods
Study design
The trial design and methods have been published previously.16 Briefly,
REFLO-STEMI was a multi-centre, prospective, randomized, open-label,
controlled trial, with blinded endpoint analysis, conducted in accord-
ance with the Helsinki Declaration. Ethical approval for the study (refer-
ence 11/H0405/10) was obtained from the National Research Ethics
Service (UK). ST-segment elevation myocardial infarction patients
with single vessel disease and thrombolysis in myocardial infarction
(TIMI) flow grades 0–1 in the IRA were enrolled between October
2011 and April 2014 in four regional cardiac centres in the UK. All pa-
tients .18 years age, presenting within 6 h of symptom onset, with
ST-segment elevation ≥2 mm in ≥2 contiguous leads and with a base-
line correctedQT interval (QTc),450 ms on admission electrocardio-
gram (ECG) were eligible and assented.16 Full eligibility criteria are
shown in Supplementary material online, Table S1.
Randomization and treatment
Patients were randomized using a 24-h interactive voice recognition ser-
vice with concealed allocation. All patients were pre-treated with aspirin
300 mg and prasugrel 60 mg or ticagrelor 180 mg1 as well as bivalirudin
0.75 mg/kg bolus plus infusion of 1.75 mg/kg/h until completion of PPCI
or continued for 4 h if clinically indicated. Bivalirudin, recommended in
all patients, was standard of care in the enrolling centres at the time of
trial initiation. Allocation was 1:1:1 to adenosine, SNP, or control (stand-
ard PPCI alone) with stratification by ‘symptoms to balloon either less
than or ≥3 h’ and ‘anterior infarction or not’. Manual thrombectomy
was mandated in all patients and the thrombectomy catheter then
used to deliver the first drug bolus (adenosine 1 mg or SNP 250 mg)
IC distal in the coronary bed, after thorough flushing of the catheter. Im-
mediately following stent deployment, and providing a repeat QTc was
,450 ms (or ,60 ms increased over baseline value), the second dose
(adenosine 1 mg if IRA was the right coronary artery otherwise 2 mg or
SNP 250 mg) was delivered over 1 min via the guide catheter (see
Figure 2).
Study outcomes
Cardiac magnetic resonance was performed at 24–96 h on a 3.0T scan-
ner (Figure 1) to determine infarct size (primary endpoint).16 Secondary
outcomes included: MVO extent assessed on early- and late-gadolinium
enhanced (EGE, LGE) images and the presence of intra-myocardial
haemorrhage (IMH) on CMR; ST-segment resolution (STR) on ECG
performed 90 min post-PPCI; major adverse cardiovascular events
(death, MI, heart failure, target lesion revascularization, and stroke; ma-
jor adverse cardiac events, MACE) within 6 months. Important adverse
events and study outcome measures are defined online (see Supple-
mentary material online, Tables S5 and S6, respectively). A clinical events
committee, blinded to patient details and treatment allocation, reviewed
and adjudicated key trial adverse events using original source docu-
ments. An independent DSMB, with an independent statistician, period-
ically reviewed trial conduct and outcome data.
Cardiac magnetic resonance analysis
Cardiac magnetic resonance was performed as previously described16
and analysis, blinded to all patient details and treatment allocation,
was undertaken offline in a central core lab (University of Leicester)
using cmr42 (Circle Cardiovascular Imaging, Calgary, Canada). Early-
gadolinium enhanced and LGE images were acquired after 1–3 and
10–15 min, respectively, following 0.15 mmol/kg gadolinium-DTPA
(Magnevist, Bayer, Germany) administration using a single-shot or seg-
mented inversion-recovery gradient-echo sequence. Early- and
late-MVO (E-MVO, L-MVO) were defined as hypoenhancement within
the infarct territory on EGE and LGE imaging, respectively. Left ventricu-
lar volumes, infarct size, myocardial oedema (area at risk, AAR), intra-
myocardial haemorrhage (IMH), and MSI were determined as described
previously.16
Sample size
To detect a reduction in infarct size from 20 to 15% of LV mass, assum-
ing a standard deviation of 10%,18–22 a of 0.05 and two tailed, with 80%
power, a total of 192 patients were required. Allowing for a drop-out
rate of 20% between PPCI and CMR resulted in a final sample size
requirement of 240 patients.
Statistical methods
Primary analysis was by intention-to-treat with a secondary per-
protocol analysis in those patients who received both doses of the
investigational drugs. Continuous variables, including infarct size, were
investigated for normality and were log-transformed when found to
be non-normally distributed. Normally distributed continuous variables
were expressed as mean+ standard deviation and compared using
t-tests and analysis of variance (ANOVA). Non-normally distributed
data were presented as median (25th–75th quartiles) and compared
using non-parametric methods (Mann–Whitney or Kruskal–Wallis).
Comparison between groups for categorical outcomes was undertaken
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using x2 tests. Potential significant confounders of infarct size (age, sex,
diabetes, anterior MI, ischaemia time and collateral blood flow to the in-
farct territory determined by the Rentrop score23) were assessed using a
forward selection procedure (statistical significance level of 5%). Multi-
variable analysis using linear regression was used to adjust for significant
confounders. Time-to-event Cox proportional hazards regression mod-
els were used to assess predictors of first MACE (both at 30 days and at
the study end) and to obtain unadjusted and adjusted hazard ratios
(HRs) with 95% confidence intervals (CIs) for adenosine/SNP vs. con-
trol. In addition, actuarial event rates of MACE by 1 and 6 months for
each intervention were reported with 95% CIs. The assumption of pro-
portional hazards was assessed by a global hypothesis test.24 No formal
adjustment for multiple hypothesis testing was used, but P-values were
interpreted cautiously. All statistical analyses were performed using
SPSS (Version 20.0. Armonk, NY: IBM Corporation) and R (Version
3.1.2. The R Foundation for Statistical Computing, Vienna).
Results
Patient recruitment is outlined in Figure 2. Two hundred and forty-
seven patients were randomized with 207 (84%) undergoing CMR.
Ten patients did not complete the CMR (due to claustrophobia or
musculoskeletal discomfort) so that the primary outcome of infarct
size was assessed in 197 patients (80% of those randomized).
Baseline characteristics
Baseline characteristics for randomized patients are presented in
Table 1 (see Supplementary material online, Table S7 for patients
completing CMR by treatment allocation). There were no significant
differences in characteristics of those randomized and those who
completed CMR.
Angiography and primary percutaneous
coronary intervention procedure details
Radial access, thrombectomy, and drug-eluting stent use were uni-
formly high (Table 2). Intra-procedural complications were similar
across all groups. However, the incidence of transient atrio-
ventricular (AV) block not requiring pacing was greater in the con-
trol arm. There was a low incidence of AV block requiring pacing
with the study drugs (adenosine 2.4% vs. SNP 1.3% vs. 0% in control
arm). The rate of transient hypotension (not requiring vasopressor
or intra-aortic balloon-pump) was almost three-fold greater (16.5
vs. 5.8%, P ¼ 0.028) in the SNP group compared with control.
Drug delivery
Both doses of investigational drugs were administered in 66/82
(80%) and 53/79 (67%) patients (adenosine and SNP, respectively).
Figure 1 Cardiac magnetic resonance Protocol. 4C, 2C, 3C ¼ 4,2,3-chamber long-axis views; SPAMM, spatial magnetization modulation; ETL,
echo train length; FOV, field of view; LV, left ventricle; SAX, short axis; SSFP, steady-state-free precession; ST, slice thickness; TI, inversion time; TE,
echo time; TR, repetition time.
S.A. Nazir et al.1912
The commonest reasons for withholding the second dose were
QTc prolongation in 30 (adenosine: 9; SNP: 21) and hypotension
in 3 (adenosine: 2; SNP: 1) patients. Failure to cross the lesion or
deploy a stent and prohibiting intra-procedural complications
accounted for the remainder.
Angiographic, electrocardiogram, and
enzymatic assessment of myocardial injury
There was no difference in the occurrence of post-PPCI TIMI flow
grade ,3 between groups (Table 2). Likewise ECG (STR.70%)
assessment of microvascular tissue perfusion was similar across
the groups. There was no statistically significant difference between
groups in peak creatine kinase levels.
Cardiac magnetic resonance assessment
of myocardial injury: primary end point
There was no statistically significant difference in the primary out-
come measure of unadjusted infarct size between groups (Table 3).
On multivariable regression analysis, adjusting for significant con-
founders, mean infarct size was increased in the adenosine group
Figure 2 Study recruitment flowchart (CONSORT). CABG, coronary artery bypass graft; CTO, chronic total occlusion; IRA, infarct-related
artery; LCA, left coronary artery; POBA, plain old balloon angioplasty; PPCI, primary percutaneous coronary intervention; RCA, right coronary
artery; SNP, sodium nitroprusside; TIMI, thombolysis in myocardial infarction.
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(mean difference 2.73, 95% CI: 20.18 to 5.64, P ¼ 0.066) when
compared with controls. This was not seen in the SNP group.
Late-MVOwas present in 67% patients and was significantly more
prevalent in the SNP arm vs. control (75.4 vs. 56.9%, P ¼ 0.029).
However, the extent of L-MVO was small and not significantly dif-
ferent between any groups. Other CMR parameters of microvascu-
lar injury (E-MVO and IMH) were also similar between groups and
none of the potential confounders were identified as being of
statistical importance by the forward selection procedure. Diagnos-
tic quality T2-weighted (oedema) imaging was only obtainable in
109 patients (55%). There were no significant differences in AAR
or MSI between groups.
Left ventricular end-diastolic and end-systolic volumes indexed to
BSA (LVEDVI, LVESVI) were significantly increased with adenosine
compared with control and this was accompanied by a non-
significant reduction in ejection fraction (EF). Left ventricular
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Table 1 Demography of the total trial population
Characteristics Adenosine (n 5 82) SNP (n5 79) Control (n5 86) P-value
Clinical
Age (years) 57.9+12.8 60.5+13.0 59.5+11.2 0.406
Male 65/82 (79.3) 66/79 (83.5) 64/86 (74.4) 0.355
Hypertension 23/82 (28.0) 26/79 (32.9) 22/86 (25.6) 0.574
Current smoking 47/82 (57.3) 41/79 (51.9) 45/86 (52.3) 0.332
Diabetes 6/82 (7.3) 12/79 (15.2) 9/86 (10.5) 0.274
Hypercholesterolaemia 17/82 (20.7) 23/79 (29.1) 11/86 (12.8) 0.035
Previous MI 0/81 (0) 3/79 (3.8) 3/86 (3.5) 0.219
Killip class .1 3/82 (3.7) 4/79 (5.1) 4/86 (4.7) 0.905
Total ischaemia time (min) 159 (124–221) 150 (122–201) 145 (105–196) 0.169
BMI (kg/m2) 27.5 (25.0–30.1) 26.1 (24.3–30.8) 27.3 (24.4–30.6) 0.659
SBP (mmHg) 137.5+25.1 133.0+23.4 135.1+23.3 0.505
DBP (mmHg) 86.6+19.2 81.8+16.4 80.5+17.0 0.067
HR (beats/min) 74.0+17.3 71.9+14.8 71.2+14.6 0.487
Cr clearance (mL/min/1.73 m2) 98.1+28.1 93.4+29.1 92.7+25.6 0.401
Anti-platelet use
Aspirin 82/82 (100.0) 79/79 (100.0) 86/86 (100.0) 1.000
Clopidogrel 16/82 (19.5) 13/79 (16.5) 12/86 (14.0) 0.625
Prasugrel 38/82 (46.3) 33/79 (41.8) 40/86 (46.5) 0.790
Ticagrelor 28/82 (34.1) 33/79 (41.8) 34/86 (39.5) 0.591
Medication on discharge
b-Blocker 72/78 (92.3) 69/75 (92.0) 73/81 (90.1) 0.867
ACE-inhibitor/A2RB 74/78 (94.9) 75/75 (100.0) 79/81 (97.5) 0.133
Statin 77/78 (98.7) 74/75 (98.7) 80/81 (98.8) 0.999
Infarct-related artery
LAD—proximal 19/82 (23.2) 18/79 (22.8) 20/86 (23.3) 0.997
LAD—other 13/82 (15.9) 15/79 (19.0) 14/86 (16.3) 0.848
LCX 10/82 (12.2) 13/79 (16.5) 18/86 (20.9) 0.314
RCA 40/82 (48.8) 33/79 (41.8) 34/86 (39.5) 0.455
TIMI flow pre-PPCI
0–1 80/81 (98.8) 72/79 (91.1) 83/86 (96.5) 0.057
2 1/81 (1.2) 5/79 (6.3) 1/86 (1.2) 0.078
3 0/81 (0.0) 2/79 (2.5) 2/86 (2.3) 0.367
Thrombus score
4–5 75/81 (92.6) 72/79 (91.1) 81/86 (94.2) 0.754
Values are mean+ SD or n (%).
ACE-inhibitors/A2RB, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery
disease; Cr, creatinine; DBP, diastolic blood pressure; HR, heart rate; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; PCI, percutaneous
coronary intervention; RCA, right coronary artery; SBP, systolic blood pressure; TA, thrombus aspiration; TIMI, thrombolysis in myocardial infarction.
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volumes and function were similar in the SNP and standard PPCI
arms (Table 3).
Clinical outcomes
Two hundred and thirty-three (94%) patients completed follow-up
(12 patients withdrew consent/refused follow-up and 2 patients
were lost to follow-up). There was a significant increase in MACE
at 6 months (15.6 vs. 2.5%, P ¼ 0.004) in the adenosine-treated
group compared with control (see Figure 3) driven by incidence
of heart failure (10.4 vs. 1.2%, P ¼ 0.016); HR 6.53 (95% CIs
1.46–29.2), P ¼ 0.01. When adjusted for potential confounders,
the observed MACE difference remained with similar hazard ratios
with P-values: P ¼ 0.018 at 30 days and P ¼ 0.01 at 6 months
(see Supplementary material online, Table S9). There was no
statistically significant difference in bleeding between groups (see
Table 4).
Per-protocol analysis
In patients who actually received both doses of adenosine therewas,
when compared with controls, a significant increase in infarct size
(%LVM, 12.0 vs. 8.3, P ¼ 0.031) and LV volumes (LVEDVI [mL/
m2], 91.4+ 14.1 vs. 84.4+ 14.6, P ¼ 0.009) and EF (%) was
reduced (42.5+ 7.2 vs. 45.7+ 8.0, P ¼ 0.027). Major adverse
cardiac events was increased in per-protocol adenosine-treated
patients compared with control at 30 days (HR 5.91 [95% CIs
1.28–27.25], P ¼ 0.036) and 6 months (HR 7.31 [95% CIs 1.62–
33.0], P ¼ 0.008). There was no increase in MACE in those who
actually received SNP compared with controls (see Supplementary
material online, Table S9 and Figure S1).
Sub-group analyses
In patients with anterior STEMI, those who received adenosine
had significantly greater IS %LVM (16.2, 9.5–25.8 vs. 9.1, 1.8–13.4,
P ¼ 0.028) and extent of L-MVO %LVM (3.7, 0.5–6.1 vs. 0.3,
0.0–2.0, P ¼ 0.008) compared with controls (see Supplementary
material online, Table S8). Furthermore, the composite secondary
clinical endpoint of death, MI, and heart failure was significantly
greater in these patients (21.2 vs. 3.1%, P ¼ 0.025) compared with
controls.
Discussion
Sub-optimal microvascular perfusion in STEMI confers additional
morbidity and mortality despite TIMI 3 flow in the epicardial ves-
sel.25 Adenosine and SNP are powerful vasodilators with pleiotropic
effects, including anti-inflammatory, anti-platelet, and immune-
modulatory actions, that have been shown to reduce IRI, particularly
when delivered IC targeting the microvascular bed.16 However, our
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Table 2 Procedural (angiographic, electrocardiographic, and enzymatic) data and intra-procedural complications
according to treatment group
Characteristics Adenosine (n5 82) SNP (n5 79) Control (n5 86) P-valuea P-valueb
Procedural data
Radial approach 70 (85.4) 70 (88.6) 79 (91.9) 0.184 0.481
Thrombectomy 81 (98.8) 75 (98.7) 80 (93.0) 0.118 0.122
DES implantation 73 (89.0) 72 (91.1) 81 (94.2) 0.226 0.452
Number of stents 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.613 0.790
Diameter of stented segment (mm) 3.5 (3.0–3.5) 3.5 (3.0–3.5) 3.0 (3.0–3.5) 0.465 0.649
Length of stented segment (mm) 26.0 (18.0–39.0) 23.0 (18.0–38.0) 24.0 (18.0–34.5) 0.585 0.833
Electrocardiographic
Baseline maximal sum of ST-segment elevation 9.0 (6.0–12.0) 9.0 (5.0–13.0) 9.0 (5.0–13.0) 0.931 0.686
Post-PCI maximal sum of ST-segment elevation 2.0 (0.0–5.0) 2.0 (0.0–5.0) 2.0 (0.0–4.0) 0.684 0.472
STR .70% 56 (68.3) 48 (60.8) 56 (65.1) 0.662 0.562
Enzymatic
Peak CK (mg/dL) 1559 (601–2804) 1171 (430–2259) 1336 (511–2632) 0.601 0.393
Intra-procedural complications
Transient AV block not requiring pacing 7 (8.5) 2 (2.5) 10 (11.6) 0.507 0.034
AV block requiring pacing 2 (2.4) 1 (1.3) 0 (0.0) 0.237 0.479
Transient hypotension not requiring vasopressor
drugs or IABP
5 (6.1) 13 (16.5) 5 (5.8) 0.938 0.028
Hypotension requiring vasopressor drugs or IABP 5 (6.1) 3 (3.8) 6 (7.0) 0.818 0.499
Ventricular tachycardia/fibrillation 5 (6.1) 3 (3.8) 5 (5.8) 0.938 0.722
Values are mean+ SD, median (interquartile range), or n (%).
AV, atrio-ventricular; CK, creatine kinase; DES, drug-eluting stent; IABP, intra-aortic balloon-pump; STR, ST-segment resolution; TMPG, tissue myocardial perfusion grade.
aAdenosine vs. Control.
bSNP vs. Control.
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results show that neither adenosine nor SNP significantly reduced
infarct size or MVO. Furthermore, IC adenosine appeared to be
associated with detrimental cardiac effects and worse clinical
outcome.
Infarct size and markers of reperfusion
injury
There was no significant difference in infarct size between the
groups, although there was a trend to significant increase in infarct
size in the adenosine group compared with controls when the re-
sults were adjusted for confounders. There was no reduction in
MSI, early- or late-MVO measured by CMR with either drug. These
results are consistent with the only other randomized trial using
CMR, which found that high-dose IC adenosine did not increase
myocardial salvage and did not reduce either infarct size or
MVO.9 The per-protocol analysis showed that patients who re-
ceived both doses of adenosine had significantly increased infarct
size, LV volumes, and reduced EF on CMR compared with the con-
trol group, which suggests not only a lack of efficacy but potential
cardiac toxicity and partial negation of any beneficial effects of
reperfusion. This effect was particularly apparent in patients with
anterior MI. Reasons for these adverse findings remain unclear
but are considered below.
The proportion of patients achieving STR .70%, as an ECG
surrogate marker of coronary vascular flow, was relatively high
and similar across groups compared with previous studies.8 – 11,17
This may reflect our recruitment of only patients who presented
within 6 h rather than within 12 h of symptom onset as in some
previous studies.7– 9,17 In REOPEN-AMI,8 STR .70% occurred in
71% of patients treated by adenosine, in 54% of patients treated
by SNP, and in 51% of patients treated by saline (risk ratio: 1.39
[1.07–1.79]; P ¼ 0.009, and risk ratio: 1.04 [0.78–1.40]; P ¼ 0.75,
adenosine or SNP vs. saline, respectively). Furthermore, in
REOPEN-AMI, the enzymatic infarct size was 30% lower in the ad-
enosine compared with the saline group but this is a greater effect
size than would be expected by the attenuation of MVO alone,
which makes interpretation difficult. However, in the absence of
corroborative AAR or infarct size data from robust imaging such
as CMR, this may imply that the adenosine group were destined
to have smaller infarcts compared with control (saline), potentially
over-estimating the benefit of adenosine in that study.
In our REFLO-STEMI trial, a positive impact of IC SNP on MVO
assessed by ECG or CMR was not seen. This is consistent with the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Cardiac magnetic resonance data according to treatment group
Characteristic Adenosine, n 5 63 SNP, n5 69 Control, n5 65 P-valuea P-valueb P-valuec
Time from MI to CMR (h) 49.0 (28.4–75.0) 49.7 (26.2–76.1) 49.0 (38.0–74.8) 0.773 0.843 0.881
Primary endpointd
Infarct size (%LVM) 10.1 (4.7–16.2) 10.0 (4.2–15.8) 8.3 (1.9–14.0) 0.062 0.160 0.133
Microvascular injury
Presence of E-MVO (n, %) 41/60 (68.3) 42/59 (71.2) 38/63 (60.3) 0.452 0.254 0.416
E-MVO (%LVM) 1.2 (0.0–5.2), n ¼ 60/82 1.0 (0.0–5.0), n ¼ 59/79 1.4 (0.0–4.3), n ¼ 63/86 0.637 0.770 0.891
Presence of L-MVO (n, %) 43/63 (68.3) 52/69 (75.4) 37/65 (56.9) 0.205 0.029 0.074
L-MVO (%LVM) 1.0 (0.0–3.7) 0.6 (0.0–2.4) 0.3 (0.0–2.8) 0.205 0.244 0.368
Presence of IMH (n, %) 20/38 (52.6) 19/43 (44.2) 16/38 (42.1) 0.358 0.850 0.619
n ¼ 34 n ¼ 38 n ¼ 37
Salvage
AAR (%LVM) 30.6+12.2 34.7+14.4 30.3+11.5 0.907 0.152 0.266
MSI (%) 60.2+23.3 63.6+24.7 67.5+23.3 0.188 0.477 0.429
n ¼ 63 n ¼ 71 n ¼ 68
Function and volumes
LVEDVI (mL/m2) 91.3+16.1 87.0+16.9 84.4+14.6 0.011 0.336 0.044
LVESVI (mL/m2) 52.3+13.8 49.1+12.7 46.1+11.6 0.006 0.155 0.023
LVMI (g/m2) 59.1+11.5 56.0+11.2 53.6+9.2 0.003 0.174 0.014
EF (%) 43.2+7.9 43.9+6.5 45.7+8.0 0.080 0.165 0.155
Values are mean+ SD or median (interquartile range) unless otherwise stated.
AAR, area at risk; BSA, body surface area; EF, ejection fraction; IMH, intra-myocardial haemorrhage; LV, left ventricular; LVEDVI, LV end-diastolic volume indexed to BSA; LVESVI,
LV end-systolic volume indexed to BSA; LVM, LV mass; LVMI, LVM indexed to BSA; MI, myocardial infarction; MSI, myocardial salvage index; E- or L-MVO, early- or
late-microvascular obstruction.
aAdenosine vs. Control.
bSNP vs. Control.
cAll groups.
dPrimary endpoint—comparison via independent t-test on log-transformed scale.
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Figure 3 Kaplan–Meier graphs showing clinical outcome. Clinical outcomes at 30 days (top) and 6 months (bottom). HR, hazard ratio; ITT,
intention-to-treat; MACE, major adverse cardiac events; PH, proportional hazards.
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REOPEN-AMI study8 and an earlier double-blind, placebo-
controlled RCT.7
The demonstration in our study, and in those of others,3,26 of fail-
ure of reduction in MVO or infarct size using adjunctive therapies,
despite an extensive body of positive experimental data, raises the
question of trial design or even whether IRI is a distinct entity clin-
ically and whether it represents exclusively ischaemic injury.26,27
Clinical outcome
There were significantly worse outcomes for the adenosine group
compared with control, largely driven by increased early heart fail-
ure events. This is a novel finding. Whilst this may have occurred by
chance, the hazard ratio is high and cannot be discounted. Our re-
sults, including definitive and significantly worse clinical outcome
particularly in those with anterior STEMI receiving adenosine, con-
tradicts the post hoc analysis of AMISTAD-II, which reported that a
3 h adenosine infusion decreased 1-month (5.2 vs. 9.2%, respective-
ly, P ¼ 0.014) and 6-month mortality (7.3 vs. 11.2%, P ¼ 0.033)
compared with placebo, and reduced the composite clinical end-
point of death or heart failure at 6 months (12.0 vs. 17.2%, P ¼
0.022).28 However, there were several methodological weaknesses
with that study including: (i) adenosine was infused intravenously
after the PCI, (ii) infarct size was measured in only 11% of patients
and by technetium-99m sestamibi single-photon emission com-
puted tomography, which may underestimate infarct size compared
with CMR; and (iii) no measure of myocardial salvage was obtained.
Furthermore, the adverse MACE signal seen with adenosine in our
study is consistent whether assessed as intention-to-treat or per-
protocol analysis, at 1 and 6 months follow-up and remains despite
adjustment for potential confounding variables. This suggests that
high-dose IC adenosine, delivered as we have indicated in this study,
may lead to significantly worse clinical outcomes.
The finding of an adverse effect of high-dose adenosine remains
difficult to explain. It could be that high-dose adenosine tends to
activate other receptors, which lead to adverse events; adenosine
has been speculated to be responsible for excess dyspnoea ob-
served with ticagrelor in the PLATO study. However, any effect
of ticagrelor on circulating adenosine levels is likely to be small com-
pared with the relatively high doses of adenosine administered in
our study. Furthermore, the distribution of ticagrelor and prasugrel
across the treatment arms was comparable (see Table 1) and there
were no significant differences in the primary endpoint or MVO for
the patients receiving ticagrelor (see Supplementary material online,
Table S8). Additionally, adenosine may mediate diuretic resistance; it
acts on renal A1-AR on afferent arterioles to reduce glomerular flow
and filtration, stimulate renin release, and enhance proximal tubular
sodium reabsorption.29 It could be postulated that cross-activation
of renal AR promoted fluid retention, increased LV volumes and ad-
vanced heart failure pathophysiology in our adenosine-treated co-
hort. Even though our finding is hypothesis generating, our data
strongly suggest high-dose IC adenosine may lead to adverse events
(possibly through cross-activation of other receptors) and probably
should not be used to prevent MVO, in the circumstances of this
trial.
Limitations
The study was open-label, which may have influenced management
of patients. However, the primary outcomewas assessed on blinded
CMR scans. The finding of an increased hazard signal with use of
high-dose IC adenosine in our study must be interpreted with cau-
tion given our relatively small sample size. The power of the study
may have been reduced due to the use of the FWHM technique,
which has better observer variability but results in lower estimation
of infarct size compared with previous studies using more conserva-
tive thresholds. Whilst we did not formally adjust for multiple hy-
pothesis tests, which might not be considered ideal, this was a
Phase II trial, and we did not want to exclude identifying potential
efficacy of either pharmacological intervention. However, even if
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Table 4 Clinical events (first event) to 6 months according to treatment group
Characteristics Adenosine (all subjects)
(n5 82)
SNP (all subjects)
(n 5 79)
Control (all subjects)
(n5 86)
P-valuea P-valueb
MACE 12 (15.0, 7.0–22.0)c 5 (6.0, 1.0–15.0)c 2 (2.0, 0.0–5.0)c 0.004 0.261
Death 1 (1.2) 1 (1.3) 0 (0.0) 0.488 0.479
TIA/stroke 1 (1.2) 1 (1.3) 0 (0.0) 0.488 0.479
MI 2 (2.4) 1 (1.3) 1 (1.2) 0.614 1.000
HF 8 (9.8) 2 (2.5) 1 (1.2) 0.016 0.607
TLR 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
Composite of death, MI, and HF 11 (13.4) 4 (5.1) 2 (2.3) 0.009 0.428
No. of patients with .1 event 3 (3.7) 1 (1.3) 1 (1.2) 0.359 1.000
Bleeding
All bleeding 4 (4.9) 2 (2.5) 5 (5.8) 1.000 0.446
Fatal bleeding 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
HF, heart failure; MACE, major adverse cardiac events; MI, myocardial infarction; TIA, transient ischaemic attack; TIMI, thrombolysis in MI; TLR, target lesion revascularization.
aAdenosine vs. Control.
bSNP vs. Control.
cValues are n (%), except for MACE (pre-defined secondary outcome) for which %s are actuarial.
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we had used a more stringent level of statistical significance, to ac-
count for testing both of our two active treatments relative to our
control group, the statistical significance of our main results would
remain unaltered. Similarly, although there was some evidence
against the assumption of proportional hazards for the primary
clinical outcome analysis (MACE by 6 months) this was not over-
whelming, and our results were further supported by actuarial
estimates of the absolute MACE event rate by 6 months.
It is possible that the dose of adenosine used in our study was
insufficient to achieve sustained activation of A2-AR;
30 We utilized
a slow-bolus dosing regimen and it could be that, owing to the short-
half life of adenosine, concentrations of adenosine were insufficient
in the microvascular bed to augment the benefits of reperfusion.
A1-AR activation at lower adenosine doses may exacerbate MVO
by promoting neutrophil chemotaxis.30 As such, delivering adeno-
sine as a continuous infusion, to ensure more prolonged availability
of adenosine in the microvasculature, may be superior to boli injec-
tions in antagonizing MVO-related processes. It should be noted
that one might still consider low-dose (50–100 mg) adenosine, as
is common in clinical practice, to reverse established slow-flow or
no-reflow when it occurs.
Conclusions
Intra-coronary adenosine and SNP did not reduce infarct size nor
MVOduring PPCI for STEMI. Furthermore, high-dose adenosine ap-
peared to be associated with adverse clinical outcomes, increased
infarct size, and reduced EF compared with control. These data sug-
gest that neither agent is effective for sub-clinical no-reflow and
should not be used routinely and prophylactically in the setting of
PPCI to prevent reperfusion injury.
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